Houston regenerative medicine company opens new lab at UH

cell therapy innovation

FibroBiologics is opening a unique new lab at the University of Houston's Technology Bridge. Photo by Natalie Harms/InnovationMap

Pete O’Heeron wants you to know that “Bohemian Rhapsody” was originally released as a B-side. What does this nugget about Queen have to do with regenerative medicine? For O’Heeron and his company, FibroBiologics, it means everything.

That’s because most scientists consider stem cells the A-side when it comes to the race to curing disease. But FibroBiologics has set its sights on fibroblasts. The most common cell in the body, fibroblasts are the main cell type in connective tissue.

“Everyone was betting on stem cells, and we started betting on fibroblasts,” says O’Heeron, who started the company in 2008 as SpinalCyte. “I think what we're going to see is that fibroblasts are going to end up winning, there are more robust, more that are lower cost cell, they have higher therapeutic values, higher immune modulation. They're just a better overall cell than the than the stem cells.”

Since a neurosurgeon and a dermatologist first introduced O’Heeron to the idea of using fibroblasts to regrow discs in the spine, the company has expanded its reach to include promising treatments for multiple sclerosis and cancer and in wound care. Imagine a world where doctors lay fibroblasts directly onto surgical incisions after surgery, cutting the time for healing in half.

FibroBiologics has organically written and filed more than 320 patents.

“It's quite a unique situation. I don’t think that in other areas of science that you have such a wide open area to go out and patent. It's just it was a brand new area nobody had been working on,” O’Heeron explains.

And soon, investors will be able to own a stake in the impressive work being forged in Houston. FibroBiologics, previously FibroGenesis, was formed in order to go public in a direct NASDAQ listing. The goal is to access the capital necessary to go to human trials. Earlier this year, the company also launched a crowdfunding campaign.

“We’ve had really fantastic results with animals and now we’re ready for humans,” says O’Heeron. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

With that in mind, the company just signed a deal with University of Houston’s Innovation Center. On Thursday, September 7, FibroBiologics will dedicate the Newlin-Linscomb Lab for Cell Therapies in the UH Technology Bridge. The new lab is named for former player and color commentator for the Houston Rockets, Mike Newlin and his wife, Cindy, as well as Pam and Dan Linscomb, a founding partner of Kuhl-Linscomb, one of the largest wealth management companies in Houston.

Other big local names newly attached to the company are astronaut Kate Rubins and Elizabeth Shpall, the director of the cell therapy laboratory at MD Anderson Cancer Center. Both have joined FibroBiologics as members of its scientific advisory board.

To fill the lab, O’Heeron says that he is adding to his team as quickly as he is able. The barrier is the fact that there are few, if any people in the world with the exact qualifications he’s seeking.

“Anytime you're breaking new scientific ground, you can't really just go out and recruit someone with that background because it really doesn't exist,” he says. But he is willing to teach and challenge scientists who are the right fit, and is hoping to expand the team in the new lab.

But like Queen did in 1975, FibroBiologics is pioneering a category of its own. And that’s something worth betting on.

From Your Site Articles
Space experts discussed the city's role in the space industry at a recent event. Photo via NASA

Overheard: Houston needs to strengthen infrastructure, workforce to maintain Space City status

eavesdropping in houston

In no time at all, humans will return to the moon and as they make the first spacewalks in fifty years — wearing suits designed in Houston — they will call down to earth, and only one city in the world will be named on the radio transmissions.

Houston is the Space City — but what will it take to maintain that moniker? This was a big topic of the Greater Houston Partnership's second annual State of Space event hosted on Tuesday, October 11.

A diverse and impressive panel discussed the Space City's future, the upcoming moon missions, commercializations, and more. If you missed the discussion, check out some key moments from the event.

"Houston has a significant role in all areas of Artemis."

— Vanessa Wyche, director of NASA's Johnson Space Center. "We have crew missions, robotic missions, and other technologies that will make up Artemis."

"The big mission we have is for Houston to remain the hub in human space flight moving forward."

— Wyche says, adding "for us to be the nexus and accelerator of research, innovation, and STEM, we need to work together for workforce development for the space economy."

"We're at a point were we can pivot to develop scalable products at a much lower cost — it really reduces the barrier of entry for commercial space partners."

— Peggy Guirgis, general manager of space systems for Collins Aerospace. "We're building in Houston because this is really an engineering hub," she adds, noting the industries and schools here that support the industry.

"Why Houston? Because of, more than anything, the sense of community."

— Steve Altemus, president and CEO of Intuitive Machines, noting the support behind building the Houston Spaceport and the existing Johnson Space Center, as well as all the other players within the space sector locally.

"At some point in the very near future we are going to land humans on the moon — the first woman on the moon, the first person of color on the moon — and we're going to say, 'Moon, Houston.' This is the only city in the world that's going to be said on those loops."

— Kate Rubins, NASA astronaut. "I feel very fortunate to be here."

"Right here in Houston — at the HoustonSpaceport, we're building a space where the Space Force can do classified work."

— Altemus says. "That's one area that I'd like to see grow."

"We need to continue to build a talent pipeline as well as generating a workforce that is able to keep pace with the rapidly growing space industry."

— Guirgis says.

"When people think about Houston, NASA has been the nexus and center of gravity, but all of Houston has been a magnet. It's a draw to come and work here."

— Rubins says. "One way to continue this is through infrastructure that's being built here — it's incredible. It's going to cement this as a place that you want to come if you're a commercial company and you want to partner with NASA, or you want to be a contractor for one of these other companies. ... And the startup scene is booming these days in Houston."

"We need to make sure that we have the world-class capabilities."

— Wyche says. "The workforce is so very important."

Here are three of the latest updates on new execs and advisory appointments from two Houston startups and a local venture group. Photo via Getty Images

3 Houston organizations announce strategic appointments across biotech and VC

short stories

Five Houston innovators have new roles they're excited about this spring. From new advisory board members to c-level execs, here's who's moving and shaking in Houston innovation.

The Artemis Fund names new vice president of finance and operations

Adrienne Mangual has a background in finance and consulting. Photo courtesy of Artemis

The Artemis Fund, a venture capital firm that funds female-founded startups with technology solutions in fintech, e-commerce tech, and care-tech, has announced a new member of its leadership.

Adrienne Mangual is the new vice president of finance and operations at the firm, joining Artemis's co-founders and general partners, Stephanie Campbell, Leslie Goldman, and Diana Murakhovskaya, along with Austin-based Juliette Richert, a senior analyst.

Mangual received her MBA from Rice University in 2019 after working 15 years in finance roles at J.P. Morgan and Key Energy Services. Over the past few years, she's worked in consulting positions with startups and technology.

"This is an exciting time to join The Artemis Fund as the fund is growing and our reach is expanding and continuing to make an impact on female founders," Mangual tells InnovationMap. "I am looking forward to supporting existing and future female founders and working with Diana, Stephanie, and Leslie as part of the team making investment decisions for the fund."

FibroBiologics appoints scientific advisory board member

Former astronaut Kate Rubins, who's spent a total of 300 days in space, has joined the a Houston company's scientific advisory board. Photo courtesy of FibroBiologics

Houston-based clinical-stage therapeutics company FibroBiologics announced the appointment of Kathleen “Kate” Rubins, Ph.D., to its scientific advisory board. A microbiologist and NASA astronaut, Rubins has conducted medical research on earth at academic institutions as well as on board the International Space Station.

“We are honored to welcome Dr. Rubins to our SAB,” says Pete O’Heeron, CEO and chairman of FibroBiologics, in a news release. “She has distinguished herself in both terrestrial research at the Salk and Whitehead Institutes and through her ethereal work on the International Space Station.

"It’s rare to have such a unique perspective on microbiology," he continues. "Dr. Rubins joins a board of world-renowned scientists who will help to guide us as we advance fibroblast cell-based therapeutics through preclinical and clinical development. We are the only company focused on this unique opportunity in leveraging fibroblasts as treatments for chronic diseases and Dr. Rubins will be a key advisor in our pursuit to bring relief to the patients.”

In 2016, Rubins completed her first spaceflight on Expedition 48/49, where she became the first person to sequence DNA in space. Most recently, she served on the ISS as a flight engineer for Expedition 63/64. Across her two flights, she has spent a total of 300 days in space, the fourth most days in space by a U.S. female astronaut, according to the release.

Cemvita Factory hires, promotes within its leadership team

Tara Karimi, co-founder and CTO, stands with Cemvita Factory's two new hires and recently promoted employee. Photo courtesy of Cemvita

Cemvita Factory has made big moves in its leadership team. The low-carbon biotech and synthetic biology solution provider has recently made three strategic appointments: Charles Nelson was hired as chief business officer, Roger A. Harris was promoted to chief commercial officer, and Alex Juminaga was recruited as head of strain development.

“Scaling to meet market demand requires the right team at the right time,” says Tara Karimi, co-founder and CTO of Cemvita, in a news release. “With Charlie, Roger, and Alex’s leadership, we’re well-positioned for growth at a time when the demand for decarbonization solutions is greater than ever.”

With over 10 years in product development, engineering, and technology commercialization experience, Nelson will oversee all aspects of sales, business development, and customer success.

“At Cemvita, we create sustainable solutions to challenges across heavy industries,” says Nelson in the release. “Our goal is to reinvent heavy industries in ways that speak to the future, reduce companies’ carbon footprints, and even create jobs; I’m delighted to help lead the charge.”

Harris originally joined Cemvita as vice president of technology commercialization a year ago and has over two decades of experience in research and development, and engineering. In his new role, he is responsible for scaling and commercializing the startup's technology.

“Cemvita is positioned incredibly well to support heavy industry in efforts to innovate, and to help oil and gas diversify offerings and reduce dependency on carbon-intensive products,” says Harris in the release. “It is an exciting time and I’m thrilled to be with Cemvita.”

Lastly, Alex Juminaga will lead the Cemvita biofoundry’s production of novel biomolecules. He brings over a decade of laboratory experience — specializing in metabolic engineering, protein expression/purification, enzyme kinetics and binding assays, analytical chemistry, and more.

“The field of synthetic biology is just getting started, with thousands of microbes yet to be discovered,” says Juminaga. “I’m excited to work alongside the brilliant scientists at Cemvita as we uncover new microbiomes and new uses for these tiny treasures.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Baylor College of Medicine names Minnesota med school dean as new president, CEO ​

new leader

Dr. Jakub Tolar, dean of the University of Minnesota Medical School, is taking over as president, CEO and executive dean of Houston’s Baylor College of Medicine on July 1.

Tolar—who’s also vice president for clinical affairs at the University of Minnesota and a university professor—will succeed Dr. Paul Klotman as head of BCM. Klotman is retiring June 30 after leading Texas’ top-ranked medical school since 2010.

In tandem with medical facilities such as Baylor St. Luke’s Medical Center and Texas Children’s Hospital, Baylor trains nearly half of the doctors who work at Texas Medical Center. In addition, Baylor is home to the Dan L Duncan Comprehensive Cancer Center and the Texas Heart Institute.

The hunt for a new leader at Baylor yielded 179 candidates. The medical school’s search firm interviewed 44 candidates, and the pool was narrowed to 10 contenders who were interviewed by the Board of Trustees’ search committee. The full board then interviewed the four finalists, including Tolar.

Greg Brenneman, chair of Baylor’s board and the search committee, says Tolar is “highly accomplished” in the core elements of the medical school’s mission: research, patient care, education and community service.

“Baylor is phenomenal. Baylor is a superpower in academic medicine,” Tolar, a native of the Czech Republic, says in a YouTube video filmed at the medical school. “And everything comes together here because science saves lives. That is the superpower.”

Tolar’s medical specialties include pediatric blood and bone marrow transplants. His research, which he’ll continue at Baylor, focuses on developing cellular therapies for rare genetic disorders. In the research arena, he’s known for his care of patients with recessive dystrophic epidermolysis bullosa, a severe genetic skin disorder.

In a news release, Tolar praises Baylor’s “achievements and foundation,” as well as the school’s potential to advance medicine and health care in “new and impactful ways.”

The Baylor College of Medicine employs more than 9,300 full-time faculty and staff. For the 2025-26 academic year, nearly 1,800 students are enrolled in the School of Medicine, Graduate School of Biomedical Sciences and School of Health Professions. Its M.D. program operates campuses in Houston and Temple.

In the fiscal year that ended June 30, 2024, Baylor recorded $2.72 billion in operating revenue and $2.76 billion in operating expenses.

The college was founded in 1900 in Dallas and relocated to Houston in 1943. It was affiliated with Baylor University in Waco from 1903 to 1969.

$50 million for Houston ibogaine research tops innovation news to know

News to know

Editor's note: The Houston innovation scene is entering 2026 with fresh funding for startups and major grants for innovative health treatments and neurological research. Here are the five most-read InnovationMap stories to start the new year, published Jan. 1-15, 2026:

1. Houston hospitals win $50M grant for ibogaine addiction treatment research

UTHealth Houston and UTMB will lead IMPACT, an initiative working toward ibogaine-based treatments for addiction and neurological issues. Photo via Pexels.

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions. The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments. Continue reading.

2. Rice scientist earns $600K NSF award to study distractions in digital age

Kirsten Adam, a Rice psychologist, is studying how the brain refocuses in the age of screens, instant gratification and other lingering distractions. Photo via Pexels.

Rice University psychologist Kirsten Adam has received a $600,000 National Science Foundation CAREER Award to research how visual distractions like phone notifications, flashing alerts, crowded screens and busy workspaces can negatively impact focus—and how the brain works to try to regain it. Adam’s work will aim to clarify how the brain refocuses in the age of screens, instant gratification and other lingering distractions. The funding will also be used to train graduate students in advanced cognitive neuroscience methods, expand access to electroencephalography (EEG) and for public data sharing. Continue reading.

3. TMC launches new biotech partnership with Republic of Korea

The Texas Medical Center and KBIOHealth have launched the TMC Republic of Korea BioBridge. Photo via LinkedIn.

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge. The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors. Continue reading.

4. CPRIT CEO: Houston’s $2B in funding is transforming cancer research and prevention

Kristen Doyle, CEO of the Cancer Prevention and Research Institute of Texas (CPRIT). Photo courtesy CPRIT.

With its plethora of prestigious health care organizations like the University of Texas MD Anderson Cancer Center, UTHealth Houston, and the Baylor College of Medicine, Houston sits at the heart of cancer research and prevention in Texas. Of course, it takes piles of cash to support Houston’s status as the state’s hub for cancer research and prevention. Much of that money comes from the Cancer Prevention and Research Institute of Texas (CPRIT). Data supplied by CPRIT shows organizations in Harris County gained $2.3 billion in institute funding from 2009 through 2025, or nearly $145 million per year. That represents almost 60 percent of the roughly $4 billion that CPRIT has granted to Texas institutions over a 16-year period. Continue reading.

5. 14 Houston startups starting 2026 with fresh funding

From groundbreaking energy leaders to growing space startups, here's who secured funding in the last six months of 2025. Photo via Getty Images

Houston startups closed out the last half of 2025 with major funding news. Here are 14 Houston companies—from groundbreaking energy leaders to growing space startups—that secured funding in the last six months of the year, according to reporting by InnovationMap and our sister site EnergyCapitalHTX.com. Continue reading.

​Planned UT Austin med center, anchored by MD Anderson, gets $100M gift​

med funding

The University of Texas at Austin’s planned multibillion-dollar medical center, which will include a hospital run by Houston’s University of Texas MD Anderson Cancer Center, just received a $100 million boost from a billionaire husband-and-wife duo.

Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed the $100 million—one of the largest gifts in UT history. The Coxes live in Austin.

“Great medical care changes lives,” says Simone Coxe, “and we want more people to have access to it.”

The University of Texas System announced the medical center project in 2023 and cited an estimated price tag of $2.5 billion. UT initially said the medical center would be built on the site of the Frank Erwin Center, a sports and entertainment venue on the UT Austin campus that was demolished in 2024. The 20-acre site, north of downtown and the state Capitol, is near Dell Seton Medical Center, UT Dell Medical School and UT Health Austin.

Now, UT officials are considering a bigger, still-unidentified site near the Domain mixed-use district in North Austin, although they haven’t ruled out the Erwin Center site. The Domain development is near St. David’s North Medical Center.

As originally planned, the medical center would house a cancer center built and operated by MD Anderson and a specialty hospital built and operated by UT Austin. Construction on the two hospitals is scheduled to start this year and be completed in 2030. According to a 2025 bid notice for contractors, each hospital is expected to encompass about 1.5 million square feet, meaning the medical center would span about 3 million square feet.

Features of the MD Anderson hospital will include:

  • Inpatient care
  • Outpatient clinics
  • Surgery suites
  • Radiation, chemotherapy, cell, and proton treatments
  • Diagnostic imaging
  • Clinical drug trials

UT says the new medical center will fuse the university’s academic and research capabilities with the medical and research capabilities of MD Anderson and Dell Medical School.

UT officials say priorities for spending the Coxes’ gift include:

  • Recruiting world-class medical professionals and scientists
  • Supporting construction
  • Investing in technology
  • Expanding community programs that promote healthy living and access to care

Tench says the opportunity to contribute to building an institution from the ground up helped prompt the donation. He and others say that thanks to MD Anderson’s participation, the medical center will bring world-renowned cancer care to the Austin area.

“We have a close friend who had to travel to Houston for care she should have been able to get here at home. … Supporting the vision for the UT medical center is exactly the opportunity Austin needed,” he says.

The rate of patients who leave the Austin area to seek care for serious medical issues runs as high as 25 percent, according to UT.

View All Listings